Diaceutics and the Precision Cancer Consortium (PCC) launched the NGS Concordance Study to benchmark how consistently variant calls match across next-generation sequencing panels and platforms used in routine clinical practice. The initiative plans to evaluate up to 20 NGS assays and compare variant results against known reference profiles in synthetic samples. The goal is to generate evidence on concordance, reduce uncertainty in biomarker testing, and support more confident clinical decision-making as NGS becomes central to matching patients to targeted therapies. Diaceutics and PCC said they are seeking laboratories, diagnostic companies, and precision-medicine stakeholders to participate. The work also reflects growing regulatory and clinical pressure for transparent performance characteristics across labs and vendors, particularly where differences in panel design and bioinformatics pipelines can affect actionable results.